Etigilimab

{
  "id": "MLC-T-ONC-013461",
  "term": "Etigilimab",
  "field": "Oncology and biomedicine",
  "definition": "A monoclonal antibody targeting the human co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, etigilimab binds to TIGIT expressed on various immune cells, including T cells, and prevents the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8-positive T cells, and leads to CD226 dimerization and CD226-mediated signaling. This activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion and the inhibition of antiviral immune responses.",
  "synonyms": [
    "WHO 10742",
    "immunoglobulin G1, anti-(human receptor TIGIT(T-cell immunoreceptor with Ig and iTIM domains)) (humanized mouse monoclonal OMP-313M32 gamma1-chain), disulfide with humanized mouse monoclonal OMP-313M32 kappa-chain, dimer",
    "anti-TIGIT OMP-313M32"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/etigilimab/"
}